Clinical Significance of Free Plasma Hydroxyproline Measurement in Metabolic Bone Disease by Minisola, S. et al.
Minisola, Antonelli and Mazzuoli: Frec plasma hydroxyproline in skeletal disorders 515
J. Clin. Chem. Clin. Biochem.
Vol. 23, 1985, pp. 515-519
Clinical Significance of Free Plasma Hydroxyproline
Measurernent in Metabolie Bone Disease
By S. Minisola, Rossella Antonelli and <7. Mazzuoli
IV ih Medical Pathology, Mineral Metabolism Service, Polyclinic "Umberto , University of Rome "La
Sapienza", Rome, Italy
(Received January 10/March 27, 1985)
Summary: Free hydroxyproline was measured in plasma of 67 normal subjects and in 70 patients with bone
disease including primary hyperparathyroidism (n = 19), osteoporosis (n = 18), Pagef's disease (n = 14),
cancer involving bone (n = 8), chronic renal failure (n = 6), and osteomalacia (n = 5). A good correlation
was found between plasma and urinary values of the amino acid in normal subjects (r = 0.66; p < 0.001).
In patients with skeletal disorders a highly significant direct correlation was observed between free plasma
hydroxyproline on the one hand and urinary hydroxyproline (r = 0.92; p < 0.001) and serum alkaline
phosphatase activity (r = 0.86; p < 0.001) on the other, even though there were a few examples of
dissociations among these parameters.
Free plasma hydroxyproline decreased in the patients with Pagefs disease following chronic administration
of salmon calcitonin. Following successful parathyroidectomy, free plasma levels of hydroxyproline decreased
in all the cases studied.
Measurement of free plasma hydroxyproline thus appears to provide a specific index of bone metabolism
that may be usefully employed äs an alternative to the assay of other markers of bone turnover.
Klinische Bedeutung der Bestimmung des freien Hydroxyprolin im Plasma bei Knochenstoffwechselerkrankungen
Zusammenfassung: Freies Hydroxyprolin im Plasma wurde bei 67 Kontrollpersonen und 70 Patienten mit
Knochenerkrankungen (primärer Hyperparathyreoidismus, n = 19; Osteoporose, n = 18; M. Paget, n =
14; Krebs mit Knochenbeteiligung, n = 8; chronisches Nierenversagen, n = 6 und Osteomalazie, n = 5)
bestimmt. Zwischen den Werten für Hydroxyprolin im Plasma und im Harn der Kontrollpersonen wurde
eine gute Korrelation (r = 0,66; p < 0,001) gefunden. Bei Patienten mit Skeletterkrankungen wurde eine
hochsignifikante Beziehung zwischen freiem Hydroxyprolin im Plasma und Hydroxyprolin im Harn (r =
0,92; p < 0,001) sowie der katalytischen Konzentration der alkalischen Phosphatase (r = 0,86; p < 0,001)
gefunden, wenn auch gelegentlich Abweichungen beobachtet wurden. Freies Hydroxyprolin im Plasma
fiel bei Patienten mit M. Paget nach chronischer Behandlung mit Lachs-Calcitonin. Nach erfolgreicher
Parathyreoidektomie fiel das freie Hydroxyprolin im Plasma bei allen untersuchten Patienten.
Die Bestimmung des freien Hydroxyprolin im Plasma ist eine geeignete Kenngröße für den Knochenstoffwech-
sel, die anstelle anderer Kenngrößen des Knochenumsatzes eingesetzt werden kann.
n ro uction so-called collagen-like protein, does not appear to be
Hydroxyproline exists in human plasma in at least related to Collagen metabolism (2), but to the Clq
three forins: free, peptide-bound and protein-bound component of complement (3, 4); the ultrafilterable
(1). The nonultrafilterable protein-bound form, the fraction, comprising both the free and peptide-bound
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hydroxyproline is, however, considered to be a reli-
able biochemical marker of bone turnover, skeletal
tissue being the major reserve of Collagen in the
human body (5, 6, 7).
Generally, the urine of persons eating a Collagen free
diet contains 95% of peptide-bound hydroxyproline.
In contrast. about 50 — 60% of hydroxyproline in
plasma, excluding the nonultrafilterable form, rep-
resents the free amino acid (7), which is metabolized
mainly in the liver by specific oxidase activity.
The present paper gives the results of our clinical
studies on plasma levels of free hydroxyproline in
patients vvith various skeletal disorders, in which
measurement of the total urinary excretion of this
amino acid is considered s useful.
Materials and Methods
Control values (mean ±SD = 8.65 ± 2.20 μηιοΐ/ΐ) of free
hydroxyproline in plasma were obtained from 67 normal
subjects (21 males and 46 females) aged between 19 and 83
years with no evidence of calcium or skeletal abnormalities
from routine history, and physical and biochemical evaluation.
Studies under basal conditions were carried out on 19 patients
with primary hyperparathyroidism, established by surgery; 15
females with postmenopausal osteoporosis and 3 males with
juvenile osteoporosis with radiological evidence of one or more
vertebral crush fractures; 14 patients with Pagef s disease of
bone, four with monostotic involvement, in each of whom the
history, physical and biochemical evaluation, X-ray and/or
bone-scan fmdings were diagnostic of this disorder; 8 patients
with bone metastases due to cancer of the prostate (3 cases),
lung (2 cases), kidney (2 cases), bladder (l case), confirmed
histologically or at autopsy; 6 patients on maintenance hae-
modialysis therapy who had radiological evidence of osteitis
fibrosa; 5 patients with histologically proven osteomalacia,
secondary to malabsorption syndrome. Plasma hydroxyproline
measurements were also repeated in 8 patients with primary
hyperparathyroidism 24 hours after removal of the adenoma
and in 3 patients with Pagef's disease of bone at l, 5, and 9
month intervals during treatment with salmon calcitonin (100
MRC U/day in two patients, or every other day in one patient).
Blood samples in all patients and control subjects were collected
after at least 48 hours on a gelatine free diet. Venous blood, in
the maintenance haemodialysis patients, was collected at least
36 hours after the last dialysis. The 24 h total urinary excretion
of the amino acid was also measured in all individuals, with
the exception of patients presenting bone metastases or renal
failure. Finally, blood samples were collected in all patients for
the determination of alkaline phosphatase activity. Free plasma
and total urinary hydroxyproline were assayed by a Standard
autoanalyser method (8); Separation of free plasma amino acid
was carried out according to the method of Husdan et al. (9).
The reported values of plasma hydroxyproline are the average
of two determinations. Plasma protein and serum alkaline
phosphatase activities (10) s well s urinary creatinine, were
determined by Standard methods used in our laboratory (11).
Alkaline phosphatase reference values r nge between 61 and
171 U/l.
Statistical analysis was performed by linear regression analysis
and Studenfs t test.
Results
Figure l shows the correlation between free
hydroxyproline in plasma and total urinary excretion
of the amino acid, -expressed s ratio to creatinine,
in the 67 control subjects (r = 0.66; p < 0.001).
Figure 2 shows individual valdes for free plasma
hydroxyproline in 70 patients with various bone dis-
orders. Analysis of the results in the entire series of
patients demonstrated a good correlation between
plasma hydroxyproline on the one hand and urinary
hydroxyproline (n = 56, r = 0.92; p < 0.001) (fig. 3)
and serum alkaline phosphatase activity (n = 70,
r = 0.86; p < 0.001) on the other. Plasma levels of
the amino acid were determined in 8 patients with
primary hyperparathyroidism immediately befofe
and 24 hours after removal of the parathyroid aden-
oma. This demonstrates that after s ccessful
parathyroidectomy the plasma levels of hydroxypro-
line tend to decrease immediately, postoperative
values showing a statistically significant drop with
respect to preoperative (41.3 ± 28.7 μιηοΐ/ΐ vs 17.0
± 9.6 μιηοΐ/ΐ; p < 0.007). The effects of salmon
calcitonin treatment upon the chosen biochemical
markers for bone inetabolism, in 3 patients with
Pagefs disease, are shown in figure 4. It can be seen
that, despite small variations, biochemical changes
due to pharmacological treatment show a similar
trend in all 3 cases; it is of interest to observe that
resistance to calcitonin treatment, appearing after
five months in the female patient with more severe
bone involvement, was adequately correlated with
the failure to ret rn to witfain the normal r nge of
the parameters under consideration.
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Fig. l. Correlation between concentration of free hydroxypro-
line in plasma and total urinary excretion of the amino
acid in normal subjects. r ^0.66 (p < 0.001), n = 67.
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Fig. 2. Individual values for free plasma hydroxyproline in 70 patients with various bone diseases. The horizontal lines indicate
mean ± SD for control subjects.
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Fig. 4. Changes in free plasma and total urinary hydroxypro-
line values and serum alkaiine phosphatase activity in
two women (tpp and middle) and one man (bottom)
with Pagefs disease of bone and different degrees of
skeletal involvement, during treatment with salmon
calcitonin 100 MRC U/day (women) or every other
d y (man). Represented are the means of duplicate
determinations.
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Discussion
In the present investigation a highly significant direct
correlation was observed between plasma levels of
free hydroxyproline and total urinary excretion of
hydroxyproline both in the normal subjects and in
the patients with various disorders of bone metab-
olism; this finding appears to confirm that free
hydroxyproline in plasma has the same origin äs
total urinary hydroxyproline, being derived from the
metabolism of both soluble and insoluble collagen
(7). According to Laitinen (7) our data therefore
indicate that measurement of the free hydroxyproline
fraction in blood may have the same diagnostic value
äs the determination of total urinary hydroxyproline.
Assay of free plasma hydroxyproline has so far been
used in clinical practice only in patients with renal
failure (l, 12) to evaluate the degree of bone in-
volvement or the response to therapy; few papers,
generally limited to patients with bone metastases
(13), have, on the other hand, appeared in the
literature to evaluate both the clinical usefulness of
plasma hydroxyproline analysis and the changes in
plasma amino acid levels in response to treatment
in other disorders of bone metabolism. We have,
therefore, assayed plasma concentrations of
hydroxyproline in 70 patients with the most common
skeletal disorders, and, simultaneously, measured
total urinary hydroxyproline excretion and serum
alkaline phosphatase activity. The results obtained
show that the assay of free hydroxyproline in plasma
may be usefully employed to evaluate skeletal turn-
over in metabolic bone diseases, in that free plasma
hydroxyproline correlates very significantly with uri-
nary hydroxyproline and serum alkaline phosphatase
activity. The finding that four patients with Paget's
disease and three patients with primary
hyperparathyroidism exhibited plasma levels of free
hydroxyproline at the upper normal limits, although
not increased to the same extent äs the urinary values,
may possibly be explained by the fact that in a limited
number of cases, plasma levels of the amino acid in
the morning may not reflect the entity of the overall
bone turnover during a 24 hour period. This hy-
pothesis would appear to be further confirmed by the
finding that in two of these patients with primary
hyperparathyroidism and in two of the patients with
Page t" s disease, the serum alkaline phosphatase activ-
ity values were also within the normal ränge. It
cannot be excluded, however, that in cases with less
severe bone involvement, the assay of all the
ultrafilterable hydroxyproline ffaction might be mofe
sensitive than assay of the free fraction only. Studies
related to this question are currently being carfied
out. Nevertheless, it should be pointed out that dis-
söciations between total urinary excretion and plasma
levels of the free amino acid have already been re-
ported in prostatic cancer patients with bone
metastates (14).
Further proof of the importance of free plasma
hydroxyproline measurement emerges from fmdings
obtained both in hyperparathyroid patients and in
patients with Pagefs disease during treatment with
salmon calcitonin. The observed rapid decrease in
plasma amioo acid levels immediately after surgery
confirms that measurement of free plasma
hydroxyproline may be considered a reliable index of
successful parathyroidectomy. Also the response to
pharmacological treatment appears to be well docu-
mented by the free plasma hydroxyproline meas-
urement. This is shöwed by a significant decrease in
plasma hydroxyproline concentration, which is re-
flected in a decrease in urinary amino acid excretion
and serum alkaline phosphatase activity in patients
with Pagef s disease during treatment with calcitonin.
In conclusion, the results presented indicate that
assay of free hydroxyproline in plasma may be em-
ployed äs a reliable iriafkeir öf bone turnover not only
in patients with renal failure but also in those with
normal renal function. The advantages with respect
to the determination of the amino acid in urine lie in
the considerably reduced analysis time and in the
absence of urine collection which, particularly in eld-
erly patients, is often inaccurate.
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